CORT ends Optime Care pact; exclusivity ended Sept 15, 2025

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) terminated its distribution services agreement with Optime Care, delivering notice on October 10, 2025, with termination effective January 8, 2026. Optime had served as a specialty pharmacy distributor for Korlym and Corcept’s authorized generic mifepristone, handling pharmacy operations, patient access, reimbursement support, claims, A/R, and reporting.

The agreement, originally dated August 4, 2017 and amended and restated April 1, 2024, had been extended through March 31, 2027 with automatic three-year renewals. Corcept previously informed Optime that, under its contractual rights, Optime’s exclusivity ended on September 15, 2025. The contract permitted termination for convenience by Corcept with 90-days advance notice, as well as customary remedies for material breach.

Insights

Pharma commercialization operations analyst

Operational shift: Corcept ends Optime pact; exclusivity already removed.

Corcept is winding down its long-running specialty pharmacy arrangement with Optime Care, effective January 8, 2026. Optime handled Korlym and the authorized generic mifepristone distribution and patient support functions. Exclusivity ended on September 15, 2025, suggesting Corcept planned a transition before full termination.

The agreement allowed termination for convenience with 90-days notice, indicating a contractual pathway rather than a dispute disclosed here. The filing does not state financial terms or replacement providers, so operational continuity depends on Corcept’s alternative channels.

Key milestone is the termination effective date on January 8, 2026. Subsequent disclosures may detail successor distribution arrangements and any effects on patient access and claims processing.

CORCEPT THERAPEUTICS INC false 0001088856 0001088856 2025-10-10 2025-10-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

October 10, 2025

Date of Report (date of earliest event reported)

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

Delaware		000-50679		77-0487658
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

101 Redwood Shores Parkway, Redwood City, CA 94065

(Address of Principal Executive Offices) (Zip Code)

(650) 327-3270

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CORT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02. Termination of a Material Definitive Agreement.

On October 10, 2025, Corcept Therapeutics Incorporated (the “Company”) delivered to Optime Care, Inc. (“Optime”) a notice of termination of that certain Distribution Services Agreement, dated August 4, 2017, as amended and restated on April 1, 2024, by and between Optime and the Company (the “Agreement”), effective as of January 8, 2026.

As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym^® and the Company’s authorized generic mifepristone medication (the “Medications”). Optime provided services related to pharmacy operations; patient intake, access and reimbursement; patient support; claims management and accounts receivable; and reporting (“Pharmacy Services”). Effective April 1, 2024, the Company extended the Agreement with Optime through March 31, 2027, with automatic renewal for successive three-year terms. On June 17, 2025, the Company notified Optime that, pursuant to the Company’s rights under Section 18.5 of the Agreement, Optime would cease to be the exclusive provider of Pharmacy Services with respect to the Medications, effective September 15, 2025.

The Agreement was subject to customary termination provisions, including the right of Optime to terminate in the event of a material breach by the Company that the Company does not cure in a reasonable period of time after receiving written notice. The Agreement further provides that the Company has the right to terminate the Agreement for convenience at any time with 90-days advance notice.

The description of the Agreement in this Current Report on Form 8-K (“Form 8-K”) does not purport to be complete and is subject to, and is qualified in its entirety by reference to the Agreement, which the Company initially filed as Exhibit 10.2 to its Quarterly Report on Form 10-Q for the three months ended March 31, 2024, filed with the SEC on May 1, 2024.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				CORCEPT THERAPEUTICS INCORPORATED
Date: October 14, 2025				By:		/s/ Atabak Mokari
				Name:		Atabak Mokari
				Title:		Chief Financial Officer

FAQ

What did Corcept Therapeutics (CORT) announce regarding Optime Care?

Corcept delivered notice to terminate its Distribution Services Agreement with Optime Care, effective January 8, 2026.

Which products were covered by the Optime Care agreement for CORT?

Optime supported Korlym and Corcept’s authorized generic mifepristone with specialty pharmacy and patient services.

When did Optime Care’s exclusivity with CORT end?

Corcept notified Optime that exclusivity ended on September 15, 2025.

Did the contract allow termination without cause?

Yes. Corcept had the right to terminate for convenience with 90-days advance notice.

How long had the Optime Care agreement been extended previously?

Effective April 1, 2024, it was extended through March 31, 2027 with automatic three-year renewals.

What services did Optime provide to CORT?

Pharmacy operations, patient intake/access/reimbursement, patient support, claims management and accounts receivable, and reporting.